Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review

Autor(es)

Simei, Joao Luis Q. ; Souza, Jose Diogo R. ; Pedrazzi, Joao Francisco ; Guimaraes, Francisco S. ; Campos, Alline Cristina ; Zuardi, Antonio ; Hallak, Jaime Eduardo C. ; Crippa, Jose Alexandre S.

• Tipo de documento: Artigo Científico
• Fonte: PHARMACEUTICALS; v. 17, n. 12, p. 29-pg., 2024-12-01.

Resumo

Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness. Outcomes: A narrative review was conducted to discuss the best evidence regarding the pharmacological profile of CBD, its efficacy, and safety within the context of regulation and perspectives on the development of new cannabinoid-based drugs. Key articles addressing the various facets of this issue were selected for comprehensive analysis. Conclusions: Clinicians and researchers may face unique challenges in understanding the pharmacological profile of CBD and the prospects for developing its clinical indications, given the heterogeneity of clinical terminologies and the quality and composition of cannabis-based medical products available on the market. More basic and clinical research that complies with regulatory agencies' testing guidelines, such as good manufacturing practices (GMPs), good laboratory practices (GLPs), and good clinical practices (GCPs), is needed to obtain approval for CBD or any other cannabinoid as a therapeutic for broader clinical indications. (AU)

• Processo FAPESP: 22/05199-9 - Investigação do perfil terapêutico do canabidiol em modelo animal do Transtorno do Espectro Autista
• Beneficiário: João Francisco Cordeiro Pedrazzi
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado